DK1622639T3 - Intravenøs injektion af ikke-neurotoksiske plasminogen-aktivatorer til behandling af slagtilfælde - Google Patents

Intravenøs injektion af ikke-neurotoksiske plasminogen-aktivatorer til behandling af slagtilfælde

Info

Publication number
DK1622639T3
DK1622639T3 DK04730516.4T DK04730516T DK1622639T3 DK 1622639 T3 DK1622639 T3 DK 1622639T3 DK 04730516 T DK04730516 T DK 04730516T DK 1622639 T3 DK1622639 T3 DK 1622639T3
Authority
DK
Denmark
Prior art keywords
cases
treatment
intravenous injection
plasminogen activators
neurotoxic plasminogen
Prior art date
Application number
DK04730516.4T
Other languages
English (en)
Inventor
Mariola Soehngen
Wolfgang Soehngen
Wolf-Dieter Schleuning
Robert Medcalf
Original Assignee
Lundbeck H As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck H As filed Critical Lundbeck H As
Priority claimed from PCT/EP2004/004626 external-priority patent/WO2004096268A2/de
Application granted granted Critical
Publication of DK1622639T3 publication Critical patent/DK1622639T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A61K38/58—Protease inhibitors from animals; from humans from leeches, e.g. hirudin, eglin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DK04730516.4T 2003-05-02 2004-04-30 Intravenøs injektion af ikke-neurotoksiske plasminogen-aktivatorer til behandling af slagtilfælde DK1622639T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EPPCT/EP2003/004608 2003-05-02
PCT/EP2003/004729 WO2004096267A1 (de) 2003-05-02 2003-05-06 Intravenöse injektion nicht-neurotoxischer plasminogen-aktivatoren zur behandlung von schlaganfall
PCT/EP2004/004626 WO2004096268A2 (de) 2003-05-02 2004-04-30 Intravenöse injektion nicht-neurotoxischer plasminogen-aktivatoren zur behandlung von schlaganfall

Publications (1)

Publication Number Publication Date
DK1622639T3 true DK1622639T3 (da) 2013-04-15

Family

ID=33395696

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04730516.4T DK1622639T3 (da) 2003-05-02 2004-04-30 Intravenøs injektion af ikke-neurotoksiske plasminogen-aktivatorer til behandling af slagtilfælde

Country Status (14)

Country Link
JP (1) JP2012077090A (da)
CN (1) CN1849133B (da)
AU (3) AU2003227721A1 (da)
CY (1) CY1114254T1 (da)
DK (1) DK1622639T3 (da)
EA (2) EA013837B1 (da)
ES (1) ES2401782T3 (da)
HK (1) HK1092045A1 (da)
IL (1) IL171636A (da)
MY (1) MY151447A (da)
PT (1) PT1622639E (da)
SI (1) SI1622639T1 (da)
WO (1) WO2004096267A1 (da)
ZA (2) ZA200703704B (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10153601A1 (de) 2001-11-02 2003-05-22 Paion Gmbh DSPA zur Behandlung von Schlaganfall
TWI445540B (zh) 2007-04-20 2014-07-21 Ajinomoto Kk 抗低體溫組成物
AR067345A1 (es) * 2007-07-10 2009-10-07 Paion Deutschland Gmbh Uso de trombomodulina para la preparacion de un medicamento trombolitico
EP2014296A1 (en) * 2007-07-10 2009-01-14 PAION Deutschland GmbH Novel strategies for increasing the reperfusion in obstructed blood vessel

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE69054B1 (en) * 1988-07-20 1996-08-07 Schering Ag Vampire bat salivary plasminogen activators
NL8902454A (nl) * 1989-10-03 1991-05-01 Stichting Centraal Lab Mutanten van de humane plasminogeen activator inhibitor 1 (pai-1), hun bereiding en toepassing, en recombinante polynucleotiden die voor deze mutanten coderende genetische informatie omvatten.
AU672584B2 (en) * 1991-09-05 1996-10-10 Schering Aktiengesellschaft Collagen-induced platelet aggregation inhibitor
DE10153601A1 (de) * 2001-11-02 2003-05-22 Paion Gmbh DSPA zur Behandlung von Schlaganfall

Also Published As

Publication number Publication date
ZA200703704B (en) 2008-08-27
AU2010200718A1 (en) 2010-03-18
JP2012077090A (ja) 2012-04-19
EA200501733A1 (ru) 2006-06-30
AU2004233601A1 (en) 2004-11-11
AU2004233601B2 (en) 2009-11-26
MY151447A (en) 2014-05-30
IL171636A (en) 2013-07-31
PT1622639E (pt) 2013-04-01
HK1092045A1 (en) 2007-02-02
WO2004096267A1 (de) 2004-11-11
CN1849133A (zh) 2006-10-18
EA013837B1 (ru) 2010-08-30
CY1114254T1 (el) 2016-08-31
ZA200509053B (en) 2007-11-28
SI1622639T1 (sl) 2013-05-31
CN1849133B (zh) 2011-03-30
AU2003227721A1 (en) 2004-11-23
ES2401782T3 (es) 2013-04-24
EA201000501A1 (ru) 2010-10-29

Similar Documents

Publication Publication Date Title
NO20055692D0 (no) Intravenos injeksjon av ikkeneurotoksiske plasminogenaktivatorer til behandling av cerebralt slag
NO20042172L (no) Insulinmolekyl med forlenget virkningstid
DK1567152T3 (da) Anvendelse af rasagilin med riluzol til behandling af amyotroph lateral sklerose
DE60325190D1 (de) Magnetisch verbesserter injektionskatheter
DK1455782T3 (da) Höjkoncentrerede stabile meloxicamoplösninger til injektion uden nåle
DE60329895D1 (de) Flüssigkeitsinjektor und Injektionsverfahren
ATE419270T1 (de) Makrozyklische inhibitoren der ns3-serinprotease des hepatitis c-virus mit stickstoffhaltigen zyklischen p2-gruppen
DK1333152T3 (da) Indkapslet væske til behandling af borehuller
DK1663287T3 (da) Anvendelse af modificerede cyclosporiner til behandling af HCV-sygdomme
DK1678185T3 (da) 2,3-dihydro-6-nitroimidazo[2,1-b]oxazolforbindelser til behandling af tuberkulose
ATE497505T1 (de) Makrocyclische inhibitoren der ns3-serinprotease des hepatitis-c-virus
FI20060154A (fi) Neurogeneratiivisten tilojen hoito
IS8275A (is) Píperasín afleiður til meðhöndlunar á HIV sýkingum
HK1095819A1 (en) Sulfur compounds as inhibitors of hepatitis c virus ns3 serine protease
EP1590442A4 (en) MACROCYCLIC HEPATITIS C SERIN PROTEASE INHIBITORS
ATE461209T1 (de) Hcv ns-3 serine protease inhibitoren
IS8142A (is) Læknislyf gagnleg til meðferðar á verkjum
DK1803718T3 (da) 4-Tetrazolyl-4-phenylpiperidin-derivater til behandling af smerter
DK1353694T3 (da) Kombinationer af ezetimibe med aspirin til behandling af vaskulære tilstande
DK1646413T3 (da) System til infusion af farmakologiske opløsninger
DK3332789T3 (da) Cladribinkur til behandling af multipel sklerose
DE602004015504D1 (de) Von injektionspräparaten
DK1727801T3 (da) Til behandling af smerter anvendelige piperaziner
DK1622639T3 (da) Intravenøs injektion af ikke-neurotoksiske plasminogen-aktivatorer til behandling af slagtilfælde
DK1687297T3 (da) Triazindimerer til behandling af autoimmunsygdomme